Clinical Trials Logo
  1. Home
  2. Overweight
  3. NCT03759743
  4. Details
NCT03759743 Clinical Trial

Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject

Overweight Clinical Trial

Official title:
a Randomised, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03759743
Other study ID # MT13-KR17OWT712
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 4, 2018
Est. completion date January 7, 2020

Study information
Verified date July 2020
Source Medy-Tox
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of LMT1-48(Probiotics) compared to a placebo in reducing the body fat in overweight subjects

Recruitment information / eligibility
Status Completed
Enrollment 97
Est. completion date January 7, 2020
Est. primary completion date August 17, 2019
Accepts healthy volunteers No
Gender All
Age group 19 Years to 70 Years
Eligibility Inclusion Criteria:

- Age between 19 and 70 years

- Overweight (25 kg/m2 = body mass index (BMI) < 30 kg/m2)

Exclusion Criteria:

- Pregnancy or breast-feeding

- Unstable body weight (body weight change > 10% within 3 months before screening)

Study Design

Related Conditions & MeSH terms

Intervention

Dietary Supplement:
• LMT1-48
capsules containing Probiotics
• Placebo
capsules that did not contain any probiotics

Locations
Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si

Sponsors (1)
Lead Sponsor Collaborator
Medy-Tox

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary change from baseline fat percentage at 12 week the body composition of the subjects was measured via dual-energy X-ray absorptiometry (DEXA) to determine at baseline and 12-week follow-up
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT02805478 - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05376865 - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers N/A
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Active, not recruiting NCT03435445 - Online Platform for Healthy Weight Loss (POEmaS) N/A
Enrolling by invitation NCT05576116 - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Active, not recruiting NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Phase 1
Completed NCT03648892 - Brain Dopamine Function in Human Obesity Early Phase 1
Not yet recruiting NCT05751993 - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions N/A
Recruiting NCT02887950 - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause N/A
Completed NCT03097237 - High Fiber Rye Foods for Weight and Body Fat Reduction N/A
Terminated NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4